CA
IBRX icon

Continuum Advisory’s ImmunityBio IBRX Stock Holding History

Continuum Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,030
Closed -$38.5K – 1800
2024
Q4 		$38.5K Hold
15,030
– – ﹤0.01% 713
2024
Q3 		$73.2K Sell
15,030
-4,991
-25% -$23.1K 0.01% 582
2024
Q2 		$127K Hold
20,021
– – 0.02% 451
2024
Q1 		$161K Sell
20,021
-1,222
-6% -$5.53K 0.02% 404
2023
Q4 		$107K Buy
+21,243
New +$66.7K 0.02% 444

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Continuum Advisory's IBRX Position: Q1 2025 in Review

Continuum Advisory sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 15,030 shares — an estimated $38.5K sold.

Continuum Advisory first reported a position in IBRX in Q4 2023 and held it in 5 quarters. The position peaked at $161K in Q1 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • Continuum Advisory reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 15,030 ImmunityBio shares in Q1 2025, an estimated $38.5K.
  • Continuum Advisory first reported a position in ImmunityBio in Q4 2023 and held it in 5 quarters.
  • Continuum Advisory's ImmunityBio position peaked at $161K in Q1 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.